Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX) [Yahoo! Finance]
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: Yahoo! Finance
target on Tango Therapeutics, Inc. (NASDAQ:TNGX) from $15 to $24 while keeping a Buy rating on the stock. The firm pointed to recent progress in PRMT5 inhibitors and RAS(ON) combinations, which the firm believes lowers the risk for the company's first-line pancreatic ductal adenocarcinoma opportunity. Stifel also included risk-adjusted first-line pancreatic ductal adenocarcinoma credit into its financial model for Tango Therapeutics, Inc. (NASDAQ:TNGX). Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX) Earlier, on March 5, Jefferies also increased its price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) from $14 to $18 and maintained its Buy rating on the stock. Jefferies pointed to the company's supply agreement with ERAS for pan-RAS. The research firm pointed out that upcoming topline data from Revolution Medicines on daraxonrasib, expected in the first half of 2026 for second-line pancreatic ductal adenocarcinoma, could set a new standard of care. Tango Th
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Is Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines? [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of VopimetostatGlobeNewswire
- Tango Therapeutics (TNGX) had its "buy" rating reaffirmed by B. Riley Financial, Inc..MarketBeat
- Tango Therapeutics (TNGX) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $30.00 price target on the stock.MarketBeat
- Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge [Yahoo! Finance]Yahoo! Finance
TNGX
Earnings
- 3/5/26 - Beat
TNGX
Sec Filings
- 4/17/26 - Form ARS
- 4/17/26 - Form DEFA14A
- 4/17/26 - Form DEF
- TNGX's page on the SEC website